跳至主要内容
临床试验/NCT03154242
NCT03154242Unknown不适用

Effect of Genetic Polymorphisms on Clinical Outcome of Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients

Ain Shams University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年3月20日最近更新:
适应症

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
Progression-free survival (PFS)

研究概览

简要总结

This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (NSCLC).
  • Eastern Cooperative Oncology Group performance status (ECOG PS) = 0-
  • Chemotherapy naïve.
  • Age >18 years.
  • Adequate bone marrow reserve

排除标准

  • Presence of Central nervous system(CNS) metastases.
  • Inadequate liver function
  • Inadequate renal function
  • Serious comorbid systemic disorder incompatible with the study.

结局指标

主要结局

Progression-free survival (PFS)

时间窗: From the date of starting the chemotherapy until the date of documented disease progression or date of death from any cause assessed up to 12 months

It's defined as the time from day 1 of chemotherapy to the day of documented disease progression or death from any cause.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Esraa Salah Abdal Hay Abdal Khalek

demonstrator of clinical pharmacy

Ain Shams University

研究点 (1)

Loading locations...

相似试验

Effect of Genetic Polymorphisms on Platinum Based... | 临床试验